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Introduction
The signs and symptoms of inammation and sepsis are widely available in historical
records [1], but the widely-accepted exact denition for the Systemic Inammatory
Response Syndrome (SIRS) and sepsis was only created in 1991 by the joint work group
of the American College of Chest Physicians and the Society of Critical Care Medicine
[2]. These denitions were renewed and accepted by the International Sepsis Denitions
Conference in 2001 [3]. At least two criteria of the currently used diagnostic criteria
must be fullled for the diagnosis of SIRS. These criteria are discussed in Table 1.1.
Table 1.1: Diagnostic criteria for the Systemic Inammatory Response Syndrome.
Body temperature > 38C, or < 36C
Heart rate > 90min
Hyperventilation respiratory rate > 20 =min, or arterial partial oxygen
pressure (PaCO2) < 32mmHg
White blood cell count > 12000 cell=µl, or  4000 cell=µl
According to the most recent denition, sepsis is the development of SIRS as a result of
proved or suspected microbiological infection. The term severe sepsis is used for sepsis
complicated with the development of at least one organ dysfunction. Septic shock is
dened as hypotension regardless of appropriate uid challenge and without any dierent
known cause. Levy emphasises the importance of bedside clinical work in the diagnosis
of sepsis. The 2001 sepsis consensus conference stated that in day-to-day work, the
notion of the patient "look septic" should be considered more important than strict
data.
The following aspecic clinical signs can help the diagnosis of sepsis [3]:
 Documented or suspected infection
 Fever (core temperature > 38:3 C) or hypothermia (< 36 C)
1
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 Heart rate > 90min or > 2 standard deviation above the normal value
 Tachypnoea
 Altered mental status
 Signicant oedema or positive uid balance (> 20ml=kg over 24 hours)
 Hyperglycemia (plasma glucose > 7:7mmol=l), in the absence of diabetes
 Leukocytosis (> 12 000 =µl), leukopenia (< 4000 =µl) or >10% immature forms
 Plasma C-reactive protein (CRP) > 2 standard deviation above the upper limit of
the reference range
 Plasma procalcitonin (PCT) > 2 standard deviation above the upper limit of the
reference range
 Arterial hypotension (< 90mmHg), mean arterial pressure  70mmHg or systolic
blood pressure drop  40mmHg or >2 standard deviation below normal for age
 Central vein oxygen saturation < 70%
 Cardiac index >3:5 l=min =m2
 Arterial hypoxia (PaO2/FiO2 < 300 =mmHg
 Acute oliguria (urine output 0:5ml=kg=h)
 Creatinine increase > 44:2 µmol l
 Coagulation abnormalities (International normalised ratio > 1.5 or activated par-
tial thromboplastin time > 60 seconds)
 Ileus
 Thrombocytopenia (platelet count < 100 000 =µl)
 Hyperbilirubinaemia (plasma total bilirubin 70 µmol=l)
 Hyperlactataemia (> 1mmol=l) or decreased capillary rell or mottling
The presence of organ dysfunctions can be early diagnosed by the above mentioned
listing, or by altered laboratory values and by clinical scores. Multiple clinical scores,
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including the Multiple Organ Dysfunction Score (MODS) or the Sequential Organ
Failure Assessment (SOFA) were developed to assist sepsis outcome prediction and
overall patient status description for clinical studies [4, 5]. Also, the current diagnostic
criteria for severe sepsis recommend the use of the SOFA and MODS scores for the
diagnosis of organ dysfunctions in adult patients [3]. As sepsis mortality is highly
aected by the number of organ dysfunctions, the development of multiple organ failure
is a serious complication of sepsis.
1.1 The epidemiology of severe sepsis
Diagnostic, therapeutic and organ-support therapy of sepsis rapidly evolved in the past
decades, while sepsis and severe sepsis are still leading causes of in hospital mortality
[6]. Angus et al. conducted extensive research on sepsis incidence and mortality in the
United States of America. According to their results, in 1995, 192980 cases suered
from severe sepsis of total 6.6 million hospital discharges studied. The national estimate
for the USA was 751000 cases annually (3.0 case / 1000 population), accounting for
20% of all Intensive Care Unit (ICU) admissions. Although incidence increases with
patient age exponentially, severe sepsis has a small incidence peak in infants. While
children in age between 5 and 14 have incidence of 0.2/1000 only, in elderly patients
(85 years and above) incidence reaches 26.2/1000. The overall hospital mortality of
severe sepsis was high, 28.6%, while the estimated sepsis-caused death rate (9.3%) was
comparable to the mortality of acute myocardial infarction in 1995. According to Angus
et al. mortality is slightly higher in adult male patients (male/female mortality: 29.3%
vs. 27.9%) and has a good correlation with patient age. Of all cases studied by Angus
et al. 73.6% had developed one organ dysfunction, while 20.7% of patients suered from
two organ dysfunctions. Only about 1% of patients had estimated mortality of 76.2%
with the development of four or more organ failures. Most patient in this study suered
from respiratory (45.8%), circulatory (24.4%), renal (22%), or haematopoetic system
dysfunction (20.6%) [6]. Angus also covered clinical studies regarding severe sepsis in his
review and found a wide range of incidence. Most data assessed originated from tertiary
academic centres and diered signicantly by the patients geological location, which may
biased the whole picture of sepsis incidence. The overall mortality based on dierent
studies was 49.7%, but this result is also controversial because of dierent study inclusion
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criteria [7]. A review by Linde-Zwirble emphasises, that dierences between ICU sta
experience and available equipment may highly aect the diagnostic and therapeutic
success of sepsis [8]. Short-term patient survival is usually determined by liver status,
haematological diseases in patient history, as well as inappropriate antimicrobial therapy.
Following 48 hours of ICU stay, chronic alcohol abuse, congestive heart failure, shock
and the number of organ failures are the main survival determinants [9].
In the year of 2005 and 2010, two opt-in audits were carried out in Hungary regarding
sepsis incidence and mortality. Both studies included a two-week period of patient
care, including 789 and 866 patients consecutively. Median age of included patients
were: 64 and 66 years, while gender ratio was 62%/38% and 50%/50% (male/female).
Patients with proved infections in 2010 (307), 64% of patients were diagnosed with severe
sepsis, while 38% developed septic shock. Overall mortality was 33%, while severe septic
patients had 39% mortality ratio and septic shock patients showed 55% mortality rate.
Presence of multiple organ dysfunction decreased in the 5 years period with near 10%.
26% of patients had 2 or 3, while 17% developed 4 or 5 organ dysfunctions. Length of
intensive care unit stay did not dier in these studies with a median of 8 and 7 days
[10]. According to Annane et al. 30-50% of septic patients have Gram-positive bacterial
infection, most commonly methicillin-susceptible Staphylococcus aureus. Gram-negative
bacteria were detected in 25-30% of all cases, while fungi account for about 6%. Viruses
and parasites share another 7% of frequency [11]. Of all patients treated with suspected
infection in Hungary, regarding to the 2010 data (307 patients), community acquired
infections were the leading cause, accounting for 59% of all cases, while in-hospital
infections decreased to 23% from the former 42%. In the cause of infection, there was
a slight shift in the 2010 data, as Gram-negative bacteria become the leading infection
sources with 53%, while Gram-positive bacteria accounted only for 41%. Also, Bogar et
al. reported a non-signicant increase of detected fungal infections from 4% to 6% [10].
The treatment of sepsis is a high burden for the social system. Angus et al. reported
an average 20 days length of stay, and about $22,100 cost per case. Non-survivor cases
showed higher costs with almost $26,000/case. For comparison, in the same study,
non-ICU patients cost $13,900/case.
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1.2 The etiology and pathophysiology of severe sepsis
1.2.1 Early response and inammatory mediators in sepsis
Sepsis is usually characterised as a result of a complex, but inappropriate response to
pathogen-associated stress. Although our current view emphasise this inappropriate
host defence, pathogens also clearly contribute to the development of sepsis through
virulence factors. Bacteria harbour cellular elements and ligands to adhere to and
colonise epithelial surfaces (including adhesins, agella and mbriae, bacterial pro-
tein secretion systems, ligand mimicry, biolm production and anti-phagocytosis) [12].
The highly conserved innate immune system is responsible for the recognition of the
"non-self" and "damaged-self" via pattern recognition receptors. Recognised pathogen-
associated molecular patterns and damage-associated molecular patterns, are conserved
and normally not expressed in healthy hosts. These patterns are present on both
Gram-positive and Gram-negative bacteria, fungi and viral limiting membranes or walls
[13, 14], or may develop as new compounds during cellular damage. Gram-negative
bacteria can be recognised by wall component lipopolysaccharide (LPS) which usually
binds to CD14 containing LPS binding complex. Peptidoglycans (Gram-positive bac-
teria wall components) and LPS may bind to Toll-like receptor-2 (TLR) and TLR-4
respectively. The TLRs were originally described as Drosophila dorsoventral pattern
determinant signalling pathway proteins, their exact role in human pathophysiology
was only recently elucidated. Medzhitov et al. demonstrated that TLRs in humans,
particularly TLR-4 vastly contributes to LPS recognition through a nuclear-factor-B
(NF-B) mediated pathway [15]. To date, at least 11 human TLR proteins are identied
[16]. These receptors contains a leucine-rich extracellular and an interleukin (IL)-1-
receptor associated intracellular part. Although TLR-1, -2, -4, -5 are recognised as
bacterial and TLR-3, -7, -8 as viral pattern receptors, most of them also have their own
endogenous ligands [17]. Increased expression of TLR-2 and TLR-4 in septic patients
compared to controls is already described [18]. Activation through TLRs induce multiple
intracellular signal-transduction pathways, including the PI3k-Akt, p38 and IB/NF-B
pathways [18]. The degradation of IB through protein phosphorylation leads to NF-
B activation. Following NF-B transports inside the cell nucleus and induce various
gene expressions, including inammatory cytokines (IL-1, IL-1, IL-2, IL-6), acute
phase proteins (C-reactive protein, LPS-binding protein), tissue factor (TF), and tissue
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factor pathway inhibitor, adhesion molecules [19]. There is increasing evidence of the
hypothesised role of apoptosis protein caspase-1 and caspase activated DNase in sepsis.
The caspase activated DNase may induce DNA fragmentation and apoptosis. The
importance of these mechanisms was conrmed in caspase-1 knock out mice, which are
evidently protected from sepsis [20]. The nucleotide-oligomerization domain leucine-rich
repeat proteins (capable to recognise bacterial peptidoglycans) and cytoplasmic caspase
activation and recruiting domain helicases are also capable to initiate innate immune
response [20, 21]. Leukocytes including monocytes, macrophages, dendritic cells, poly-
morphonuclear leukocytes, B-, T-, and NK cells as well as platelets also express TLRs.
Leukocytes activated through TLRs release pro-inammatory cytokines, including IL-
1, IL-6 and tumour necrosis factor alpha (TNF-) which activates the innate immune
system and surrounding cells leading to further cytokine release (cytokine storm, as
referred earlier). Activated leukocytes may leave the circulation and migrate towards
damaged tissues, while released pro-inammatory cytokines induce the production of
eicosanoids and platelet-activating factor, further increasing vascular permeability and
platelet activation [11]. Also, complement system proteins C3a and C5a anaphylatoxin
release from mast cells and basophils increase vascular permeability and smooth muscle
contraction. The equilibrial cross-talk of endothelial cells and surrounding circulating
cells is impaired during sepsis. Structural and functional changes of endothelial cells
include swelling, blebbing, contraction, and detachment from subendothelial surface.
Functional changes enhance leukocyte attachment, rolling a diapedesis, as well as the
activation of the coagulation cascade [19, 22, 23]. Genetic polymorphism is a strong
determinant of inammatory cell activation. TNF- gene promoter region, or TLR4
receptor polymorphisms may determine the levels of cellular activation, shaping the
course of inammation. An amino acid change (position 532) in IL-1 receptor associated
kinase-1, which is present in 25% of Caucasian population may cause increased NF-B
activation leading to increased mortality rate [24].
Contrary to pro-inammatory response, the release of anti-inammatory substances and
the development of Compensatory Anti-Inammatory Response Syndrome (CARS) is
also present in sepsis [11, 25]. Bone hypothesised, that an eective anti-inammatory
immune suppression is already developed in patients with severe inammatory diseases,
explaining the harmful eect of inammation suppression therapies [26, 27]. CARS
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itself seems not only the sings of amelioration following SIRS, but an existing patho-
physiological phenomenon. There is evidence for anti-inammatory IL-10, -4, -6, -13
and transforming growth factor- and interferon- production. Cellular contributors to
immune responses are also aected by CARS. In the process of leukocyte reprogram-
ming, neutrophil-driven inammation limitation and neutrophil clearance is deteriorated
through delayed apoptosis. This characteristic may sustain inammation and organ
injury [22]. Monocytes have diminished antigen presentation potential and cytokine
production shifted towards anti-inammation, while leukocyte anergy and decreased
responsiveness to mitogenic stimuli is characterised in patients. Septic patients also
show increased levels of Th2 T helper cells, which shifts the immunoresponse towards
anergy [22, 25]. The antagonism with inammatory response of novely identied factors,
including macrophage inhibitory factor, an early acting factor in sepsis and high-mobility
group box protein type-1, a late acting cytokine of inammation may have high impact
on disease progression and increase patient survival [22].
1.2.2 Development of organ dysfunctions in severe sepsis
The exact mechanism behind the development of sepsis-related organ failures is yet to be
elucidated [22]. Although microcirculatory deterioration and intravascular clot forma-
tion are often addressed as a cause of sepsis-related organ dysfunctions, the anatomical
appearance of organs from non-survivors, the lack of evidence for massive coagulation
emphasises the role of inammatory mediators, including TNF-, IL-1, nitric oxide and
reactive oxygen species. On cellular level, these mediators may inhibit the respiratory
chain in mitochondria, leading to intracellular hypoxia and reduced ATP availability.
This may lead to DNA, protein and lipid membrane oxidation and damage. The
development of mitochondrial impairment because of poly(ADP-ribose) polymerisation
is a known cause of cell death, vascular hyporeactivity, endothelial and epithelial function
degradation [28]. Altered vascular function is a key contributor to the development of
sepsis-related organ failures. Own TLR receptors of the endothelial lining, as well as the
presence of inammatory cytokines activate endothelial cells, decreasing thrombomod-
ulin concentration and increasing TF and plasminogen activator inhibitor-1 presence.
Activated endothelial cells provide procoagulant surface and support the sequestration
of polymorphonuclear cells. Increased TNF- concentration supports swelling through
endothelial cells, causing local oedema, deterioration of oxygen diusion and loss of
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intravascular uid. Cardiac output is usually elevated in patients recently diagnosed
with sepsis. This hyperdynamic circulation is maintained by heart ventricle dilatation
(because of uid therapy), while myocardial function is also aected by inammatory
cytokines (TNF-, IL-1, nitric oxide) and mitochondrial dysfunction. This functional
impairment will be a leading cause of systolic and diastolic dysfunction. In the compen-
sated phase, capillary rell is still maintained, clinically the patient present a warm skin
temperature and increased metabolism. Fluid loss via vascular swelling, intravascular
uid redistribution through vascular tone loss, myocardial dysfunction and vasodilata-
tion leads to hypotension. The rst clinical signs of circulatory decompensation are:
decreased turgor of the skin, the drop of systolic blood pressure 90mmHg and increased
lactate levels. During circulatory shock, mean arterial pressure 70mmHg disturbs
coronary circulation. Stagnant blood in vessels increase local intravascular pressure,
supporting swelling and oedema. The vascular reactiveness to nitric oxide, or local
levels of NO and metabolites, as well as the activation of vascular potassium levels and
hormone changes (corticosteroids) together may result in these alterations. However,
these vascular changes are not globally equal in the whole vasculature, leading to over
and underperfused specic tissue areas [22].
Loss of renal function aects about 50% of severe septic patients. Besides formerly
discussed factors, the direct eect of nitric oxide, angiotensin and endothelin on renal
tissue is hypothesised. Autoregulated renal circulation is impaired because of increased
catecholamine levels, while endothelial damage of renal vessels support microaggregate
formation and leukocyte diapedesis towards renal parenchyma, causing tubular cell
dysfunction. The development of metabolic acidosis, increasing creatinine and blood
urea nitrogen (BUN) levels, nally potassium level increase are the best clinical signs of
deteriorating renal function. Acute sepsis-related renal function impairment is assessed
by the RIFLE criteria (Table 1.2).
One of the most serious complication of sepsis is the development of acute lung in-
jury and acute respiratory distress syndrome [30]. The exact mechanism behind the
development of both syndromes are not fully elucidated. Destruction of the alveolo-
capillary membrane, impaired gas diusion and surfactant dysfunction are the main
contributors. Capillary damage is characteristic to the previously discussed alterations,
protein rich uid, and activated neutrophils may reach the alveolar space through
damaged endothelial cells. By the detachment of alveolar and bronchial epithelial cells
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Table 1.2: The RIFLE (Risk, Injury, Failure, Loss of function and End-stage kidney)
criteria for sepsis-related acute kidney injury [29].
Class Glomerular ltration rate Urine output
Risk Serum creatinine  1.5 < 0:5ml=kg=h  6 hours
Injury Serum creatinine  2 < 0:5ml=kg=h  12 hours
Failure Serum creatinine  3 or
serum creatinine  354 µmol=l
with an acute rise > 44 µmol=l
< 0:3ml=kg=h  24 hours
or anuria  12 hours
Loss Persistent acute renal failure = com-
plete loss
of renal function > 4 weeks
End-stage kid-
ney disease
End-stage kidney disease > 3
months
a hyalin membrane lls the alveoli, while the cytokine production of local macrophages
activate neutrophils. These activated cells release proteases, produce reactive oxygen
species, increasing local tissue damage, while surfactant is inactivated by the protein
rich uid [31]. Reparation processes starts immediately following tissue damage. Type
II pneumocytes proliferate to restore alveolar structure, while oedema leaves the alveolar
space through active transport and protein components are phagocyted. The increase
of alveolar closing capacity and the decrease of functional residual volume will cause the
collapse of the alveoli. Unventilated alveoli increase the shunt circulation in the lungs,
increasing the oxygen need of patients [31, 32].
The reaction of the neurohormonal system can be described as an "ebb and ow". The
ebb phase is characterised by the stresshormone release, sympathetic system activation,
impaired glucose tolerance and peripheral insulin resistance, increased lipid degradation.
In the ow phase inammatory cytokines develop the clinical picture of sepsis. Degraded
proteins are mainly of skeletal muscle origin, further complicating the renal impairment.
The direct eect of inammatory cytokines and worsening hepatic and renal function will
result in the development of neuropathies and sepsis-induced encephalopathy, increasing
the ventilation period of patients [33, 34].
The contribution of coagulation in the process of organ dysfunction development may
be due to the aforementioned vicious circle of bidirectional communication between
inammatory and coagulation pathways (Figure 1.1) [22, 25, 35].
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Figure 1.1: Development of sepsis-related multiple organ failure. [22] (with written
permission from original author).
1.2.3 Altered coagulation status in sepsis
In severe sepsis, the classical components of Virchow's triad (increased coagulablity,
endothelial injury and impaired blood ow) for altered haemostasis are all present [23].
Released cytokines and activated immune cells vastly contribute to altered coagulation
state and shift towards procoagulation in sepsis. Coagulation proteases and anticoagu-
lant proteins may bind to their cellular receptors, modulating cytokine release and cell
activation. Endothelial cells may respond to and also release cytokines, while increasing
expression of adhesion molecules and growth factors. These factors promote inamma-
tory response and contribute to tissue factor mediated thrombin generation, dysfunc-
tional anticoagulation and deteriorated inhibition of brinolysis [19]. The formation of
intravascular clots may deteriorate tissue perfusion causing local hypoxia. According
to Nduka and Parillo, the complex bidirectional connection between coagulation and
inammation results in a vicious cycle of tissue injury, organ dysfunction and cell death
(Figure 1.2).
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Figure 1.2: Major pathways involved in inammation and coagulation (+ signs
stimulatory eects, - symbol state for inhibitory eects). Abbreviations used: IL,
interleukin; PAI-1, plasminogen activator inhibitor-1; TAFI, thrombin activatable
brinolysis inhibitor; TNF, tumor necrosis factor; u-PA, urinary plasminogen activator;
u-PAR, urokinase-type plasminogen activator receptor [36] (with written permission
from original author).
1.3 Therapy and organ support of severe septic patients
Although various sepsis biomarkers are of extensive research, regrettably a specic
and sensitive marker of sepsis is yet to be identied [11]. However, widely used C-
reactive protein (CRP) and procalcitonin (PCT) inammatory markers can help in the
dierential diagnosis from other causes of shock [11, 37, 38]. Following the diagnosis of
severe sepsis, initial goal-directed uid therapy and prompt, broad-spectrum empirical
antibiotic treatment (within 1 hour) are the current priorities of early therapy. The
Surviving Sepsis Campaign 2008 guideline (SSC2008) recommends uid resuscitation
with clearly dened goals, based on the results of the study by Rivers et al. (Table 1.3)
[38, 39]. Both crystalloids and/or colloids can be used for uid therapy. Following initial
steps, microbiological specimen should be collected as soon as possible, but this must not
delay the administration of antimicrobial treatment [40, 41]. Microbiological sampling,
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Table 1.3: The early goal-directed uid treatment target parameters [39].
Central venous pressure 8  12mmHg
Mean arterial pressure > 65mmHg
Urine output 0:5ml=kg=h
Central venous (v. cava sup.) oxygen saturation  70%
identication and antibiotics susceptibility testing are still the "gold standard" method.
Currently the de-escalative use of antibiotics is supported. Wide-range empirical an-
timicrobial treatment should be the rst choice treatment, based on the possible source
of infection. Based on microbiology results and clinical picture, medication should be
reconsidered and a single targeted treatment is preferable. According to the rational of
the SSC2008, early narrowing of the antimicrobial eect may decrease the possibility
of fungal (Candida), Clostridium or multiresistant Enterococcus infections [38]. Besides
proper antimicrobial treatment, infection source identication and sanation are also
important steps [42]. In case of interventional need for source control, the least invasive
access is recommended. If clinicians are not aware of any possible infection source, the
presence of systemic infection must be proved by microbiological sampling. This may
include blood cultures, pharyngeal or tracheal specimen, intraluminar catheters, wound
discharge and/or bronchoalveolar lavage uid [38].
As patients usually develop arterial hypotension despite of uid resuscitation, continuous
vasopressor therapy is necessary to maintain mean arterial pressure of 65mmHg [43,
44]. The actual guideline does not prefer norepinephrine or dopamine above the other,
but recommends epinephrine in case of anergy against these medications. The use
of corticosteroids is long debated in sepsis therapy [45, 46]. It is known that septic
patients have deteriorated corticohormon levels, but the current guideline recommends
substitution only in case of ineective vasopressor therapy [38]. Formerly wide-accepted
"renal protective" low-dose of dopamine is not proven by the meta-analysis of Kellum
et al. [47] therefore the use of this therapy is not recommended.
Blood product transfusions may be necessary when haemoglobin levels reach < 70 g=l,
in the absence of cardiac complications, while coagulation disorders should be resolved
by the administration of fresh frozen plasma [48, 49]. Platelet transfusions should be
considered if platelet count ranges in 5000  30 000 =l. Invasive procedures may require
50 000 =l, while patients below 5000 =l should receive supplementation regardless of
bleeding complications.
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Supportive therapy of sepsis is aimed to bridge the period of severe sepsis, while sup-
porting the function of sepsis-aected vital organs. Patients developing acute respiratory
distress syndrome may require mechanical ventilation. These patients should be ven-
tilated with low tidal volumes (about 6ml=kg) and plateau pressures ( 30 cmH2O)
and head of the bed elevated by 30. To minimise pressure and volume related lung
injuries, permissive hypercapnia is allowed [50, 51]. Patients must be sedated during the
time of mechanical ventilation, while neuromuscular blockade seems not to be benecial
for patients. Glucose levels of patients should be controlled by the administration of
short-acting insulin (or analogues), maintaining blood glucose levels < 8:3mmol=l [52].
Continuous or intermittent renal replacement therapy should be considered in patients
with renal impairment [53]. Deep vein thrombosis prophylaxis can be managed by the
use of low molecular weight heparin and unfractionated heparin, but high-risk thrombosis
patients should receive low molecular weight heparins [54]. For stress ulcer prophylaxis,
histamine H2 receptor inhibitors or proton pump inhibitors can be used, but these
medications may increase the risk of ventilation associated pneumonia [38, 55].
Utilising the recommendations of SSC2008, according to the review of Levy et al., overall
mortality decreased by 5.4%, in centres following guidelines for at least 2 years. This
review claims, the use of board spectrum antibiotics, proper microbiological sampling
and treatment, as well as blood glucose control are responsible for the improved survival
of patients [56].
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1.4 Platelet activation and platelet aggregation
Platelets are megakaryocyte produced cellular fragments with the diameter of 2  
5 µm and thickness of about 0:5 µm. Their average lifespan in the circulation is 7-10
days. Aged platelets are removed from blood in the spleen. Platelets surface show
an open canalicular system, connected "tunnels" of platelet membrane folds. Spe-
cic glycocalyx elements of platelet outer surface, called glycoproteins (GP) contribute
to various platelet functions. Principle GPs involved in the main platelet function,
haemostasis are GP Ib-V-IX and GP IIb-IIIa. While former is involved in platelet
shear-stress based activation and in the binding of von Willebrand factor (VWF) and
collagen, the later is responsible for brinogen binding of activated platelets and in
the formation of platelet aggregates. These receptors are able to move horizontally
in the membrane even inside the canalicular system. This movement enables to in-
crease local receptor density in case of activation. Platelets harbour dierent types
of inner vesicles of various physiological functions. The -granules contain proteins
synthesised in megakaryocytes, including: coagulation factor V, thrombospondin, P-
selectin, and VWF. Dense bodies are comparably smaller than -granules and are easily
recognised in transmission electron microscope images by the electron dense inner sphere
surrounded by an almost clear space inside the granule membrane. Dense bodies are rich
in adenosine-triphosphate and -diphosphate (ATP and ADP), pyrophosphate, calcium,
and magnesium. According to analytical electromicroscopy, the dense core is formed
by calcium complexes of pyrophosphate and serotonin. Few lysosomes are also present
in platelets, but their exact role are still debated. Commonly accepted view is they
are simple remnants from megakaryocytes [57]. Platelet function is highly regulated
by the surrounding endothelial lining and various factors. Nitric oxide, prostacyclin
and the ecto-nucleotidase CD39 through an ATP-adenosine pathway (ADP cleavage
to AMP) are all able to inhibit platelet activation and aggregation in physiological
situations [58]. Nitric oxide inhibits platelet activation acting on guanilate cyclase, while
prostacyclins and analogs increase cyclic-AMP through Gs-proteins. Classically, platelet
aggregation is discussed in 3 consecutive steps: initiation, extension and perpetuation.
The initiative activation may rise from exposure of collagen and VWF following vascular
wall injury, gathering a monolayer of activated platelets lining the injury site. Collagen
acts through 21 and GPVI, increasing platelet Ca2+ through a phospholipase C2
mediated way, while VWF activates through GPIb and 2b3 receptors. The VWF
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is crucial in platelet adhesion and rolling in high-shear situations, where VWF have
a linear structure compared to low-shear where VWF has a globule like form [59].
The initial binding cause a smaller Ca2+ peak in platelets, resulting in the release
of ADP. ADP can act on the P2Y1 receptors of resting platelets, activating platelets
locally in a positive loop in a Gi-protein coupled manner, decreasing intraplatelet cyclic-
AMP levels. Following rm adhesion to VWF through 2b3, an increased Ca2+
surge precedes platelet aggregation. From various collagen receptors, GPIV plays a
pivotal role in platelet activation and aggregation. Other possible form of activation is
through PAR receptors in the presence of thrombin, usually reported in inammatory
and thrombotic diseases. Patients receiving heparin can have platelet activation through
FcR-IIA, while pathogens (mainly bacteria and fungi) may act both on FcRs and TLRs.
The extension phase is mainly a positive loop of platelet activation, initiated by the
monolayer of activated platelets. Among many other molecules, these fragments secrete
thromboxane A2, ADP and help local thrombin formation, activating resting platelets of
the circulation. These activating substances induce phospholipase C activity in platelets,
increasing internal Ca2+ levels and the presence of surface 2b3. The 2b3 complex
changes its conformation following the binding of phosphorylated talin [60]. Binding of
brinogen bres and platelet plug formation is mainly developed through these receptors.
In the perpetuation phase, G-protein coupled receptor signals are already faded, integrins
and receptor tyrosine kinase signalling is responsible for platelet plug stability [58,
61]. Besides the classical role of platelets in haemostasis, their contribution to innate
immune response is of high interest. The review of Beaulieu et al. summarises platelet
reactions to pathogens and pathogen associated patterns. The activation of platelets
through TLR-2 may induce PI3K-Akt-Erk pathway activation, causing platelet adhesion,
aggregation, -granule secretion and reactive oxygen species production, while TLR-4
activation and signal transduction through MyD88 cause cytoskeletal rearrangement,
-granule secretion and aggregation [62].
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1.5 Microparticles in circulation
The rst description of microparticles (MPs) came from Wolf, in 1967, who rst noted
them as platelet-dust in platelet free plasma. He proved their procoagulant activity and
that this feature is removable by ultracentrifugation [63]. Although platelet-dust was
known for more than four decades, the technical diculty of MP measurement withheld
their extensive analysis until the last decade. Nowadays we are aware that hypothetically
all eukaryotic (and some prokaryotes) cells are capable of forming MPs, even though in
the circulation of healthy individuals small amounts of MPs are present, most of them
harbouring platelet-specic proteins (>80%) [64].
There was and still is a confusion in the naming of dierent bodily uid vesicles.
Throughout my thesis, I aim to use the phrase microvesicles for MPs and exosomes
together, while the denition used for MPs is the widely accepted, 100 1000 nm vesicular
fragments produced by cell membrane shedding. Exosomes are <100 nm doughnut-
shaped vesicles, generally produced during exocytosis from multivesicular bodies, or
also by membrane blebbing [65].
1.5.1 Production and elimination of microparticles
Generally thought MPs are formed during the loss of membrane phospholipid asym-
metry. Under normal resting conditions phosphatidylserine (PS) and phosphatidyleth-
anolamine is located mainly in the inner leaet of the membrane, while phosphatidyl-
choline and sphingomyelin are abundant in the outer leaet [66, 67]. This asymmetry
is sustained by the ippase enzyme transferring aminophospholipids (PS and phos-
phatidylethanolamine) into the cytoplasmic membrane layer. During cell activation,
apoptosis or increased shear stress the presence of PS in the outer leaet is one of
the rst signs of this processes [68]. Besides random phospholipid movement, the
activation of oppase(s) (an enzyme capable to direct aminophospholipids towards the
outer leaet) and scramblase (enzyme catalysing random movement of phospholipids)
accelerate the appearance of PS in the outer membrane. According to the "classical"
view of MPs production, intracellular Ca2+ increase is the main determinant of MP
formation. Calcium-induced degradation of cytoskeleton by calpains and the transient
mass dierence between membrane leaets support the formation of MPs and (Ca2+)
inux following cell activation may inhibit ippase and activate oppase enzymatic
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activity [69, 70](Figure 1.3).
Figure 1.3: Cellular mechanisms of microparticle formation, by Morel et al. [71] (with
written permission from original author).
Several signal transduction pathways are known to be involved in MP formation. Phos-
phorylation state of intracellular compartments as well as myosin light chain kinase,
calmodulin and other calmodulin-related proteins are known to be responsible for pla-
telet MP formation [72]. For platelets, stable Ca2+ levels are necessary to prevent
platelet activation and particle formation. Ca2+-dependent ATPases pump calcium
ions back into the sarcoplasmatic and endoplasmatic reticuli, or out from platelets.
Calcium concentration may increase by agonist-dependent pathways (store-operated
calcium entry) or through the purinerg P2X1 receptors [73]. The store-operated entry
pathway causes a rapid PS exposure without receptor-ligand interactions. In human
erythroleukaemic cell line this pathway is regulated by the RhoA GTPase, instead of
ROCK [74]. The importance of the storage-operated pathway is hypothesised by the
protection of collagen-induced arterial thrombus formation by the inhibition of Orai1
and STIM1 key proteins of this pathway. In platelets, STIM1 translocates from the
dense tubuli into the membrane and co-localise with Orai1 upon store-depletion, to
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facilitate extracellular Ca2+ uptake [75]. Another Ca2+ entry pathway is thrombin-
induced. Even in the lack of Orai1 and STIM1 function, thrombin is still able to
induce PS externalisation and thrombus formation [76, 77]. Also, cyclic adenosine
monophosphate-dependent protein kinase activation reduced activation-dependent MP
formation of platelets, while inhibition of this protein increased shedding. In HEL cells,
the activation of ERK1 and ERK2 kinases by calcium ionophore A23187 induced PS+
MP formation, while ERK inhibitors reduced MP shedding [78]. Endothelial cells tend
to produce MPs following TNF- activation, but this eect can be inhibited through
p38 mitogen-associated protein kinase inhibition [79]. Also, IL-1 treated endothelial cells
tend to produce MPs in the presence of thrombin. Cytoskeletal reorganisation can be
triggered by the activation of caspases or calpain. Caspases are known to take part in
cell apoptosis [80]. These proteins are able to cleave lamin-1, gelsolin, talin and also
myosin [81]. The induced activation of caspases in platelets resulted in proportional PS
exposure and membrane blebbing in the study of Schoenwaelder et al. Other vascular
cell lineages are also producing MPs following caspase activation [82]. Research on
Jurkat T-cells provided information regarding caspases and cytoskeletal reorganisation
leading to MP formation. The cleavage of ROCK I kinase by caspase-3, or ROCK II
activation by caspase-2 can both induce particle formation. ROCK I and II Rho kinases
are responsible for myosin light chain phosphorylation which induce cell contraction
and MP release during apoptosis. Regardless of the cause of PS+ MP release, the
presence of these particles may start a positive loop of further PS-MP release from
previously resting endothelial cells and platelets [72, 83]. Although the above described
mechanism is the currently accepted model for MP formation, certain data question the
single role of Ca2+ concentration in MP shedding. Most of our knowledge based on the
use of Ca-ionophores [84]. These compounds are able to increase intracellular Ca2+,
triggering membrane changes even without storage-operated pathway activation [85].
This eect of ionophore treatment is widely used in microparticle shedding assays, while
the normalisation of cytosolic-cytoplasmatic Ca2+ levels may reduce particle numbers.
Other research data implicates not only Ca2+, but other electrolyte uxes may cause
the release of particles. Ca2+-sensitive K+ channels (Gardos channels) may cause the
eux of potassium, causing cell dehydration and PS exposure in platelets.
Outer membrane composition of MPs in the circulation of mainly platelet origin consists
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of cholesterol (about 60%), sphingomyelin, phosphatidylethanolamine and PS [86], while
synovial uid particles (possibly originating from leukocytes) harbour phosphatidyl-
ethanolamine, sphingomyelin, phosphatidylcholine, lysophospholipids (20-25%) and PS
[87]. Besides physiological membrane components Huber et al. found oxidised lipid
compounds in endothelial MPs following oxidative stress, which were absent following
ionophore activation [88]. Protein composition of particles generally follow their host
cells, which can be used in particle origin characterisation. Platelet-derived MPs (PMPs)
harbour glycoproteins (GP) and dierent proteins characteristic for resting platelets, as
well as ones expressed in activated platelets (see Table 1.4). Besides PS bearing MPs
an another group of MPs are PS negative. There is still a debate on the actual number
and role of these MPs, as labelling of PS by annexin V is highly dependent on pH and
the presence of Ca2+. Characteristics of these vesicles are not completely clear. Some
hypothesise that the loss of PS is due to interaction with other membrane vesicles, cell
debris and lipophilic proteins [71].
Table 1.4: Constitutional and activation-dependent markers and representative
antibody clones of platelets and platelet-derived microparticles, generally used in ow
cytometry measurements [89].
Epitope Antibody clones
Constitutional markers:
glycoprotein Ib 6D268, N-19, C-20
glycoprotein IX GR-P, Beb1, ALMA.16
glycoprotein IIb 5B12, VIPL3, HIP8
glycoprotein IIIa F11, VIPL2
Platelet endothelial cell adhesion molecule-1
(also present on endothelial MPs)
CD31
Activation markers:
glycoprotein IIb-IIIa brinogen
binding conformation
PAC1
P-selectin exposure from -granules S12, AC1.2, AK-4
CD40 ligand TRAP1
Factor Va binding V237
Factor VIII binding 1B3
Our knowledge regarding the elimination of MPs is considerably limited. Rank et al.
followed MP numbers after platelet transfusion in patients suering from aplastic phase
of haematological diseases. According to their data, transfused MP half-life was 5-6
hours. Phagocytosis by macrophages, as well as the role of lactadherin (binding and
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phagocytosis by platelets and leukocytes) is hypothesised in the removal of MPs from
circulation [90].
1.5.2 Role of microparticles in (patho)physiological processes
Vesicle formation is a conserved process of cells to exchange information with their
environment [91]. Even by prokaryotes, outer membrane vesicles are used for com-
munication, protection and for the horizontal exchange of genetic information. These
vesicles are 50  100 nm in size and may be considered as exosomes [92]. Pseudomonas
aeruginosa, a human opportunist Gram-negative bacteria, commonly identied in sepsis,
use membrane-derived vesicles in quorum sensing, the process of local population density
perception. Removal of P. aeruginosa membrane-vesicles inhibited bacterial cell-cell
communication, through the removal of Pseudomonas quinolone signal transmitted by
vesicles [93]. Enterotoxic Escherichia coli strains produce membrane vesicles, containing
heat-labile endotoxin. These vesicles are able to transport toxin into host cells, therefore
take part in the development of traveller's diarrhoea [94]. The O157:H7 E. coli strain is
able to produce vesicles containing DNA, RNA, phospholipids, LPS and various proteins.
According to Yaron et al., these vesicles may fuse with Salmonella enterica to share DNA
content and expressed in S. enterica genes from E. coli [95].
There is a growing evidence, that eukaryote cells also utilise vesicles in a wide variety of
(patho)physiological processes.
In the last more than 20 years MPs were more and more extensively researched in the
eld of coagulation following the observation of Wolf. Key aspects of this eect is the
distribution of TF in the circulation via small vesicles, cell activation and presentation
of extensive negative PS surface for the haemostatic system. Following activation and
shedding, PMPs (possibly following TF exchange with monocytes or monocyte-derived
vesicles) express TF, surface receptors and ligands able to bind to various cells, including:
macrophages, neutrophils and other resting platelets [96]. As reported by del Conde
et al., monocyte/macrophage derived vesicles, are able to fuse with activated platelets,
through a PS and P-selecting glycoprotein ligand-1 derived pathway. This fusion delivers
TF, from TF-rich monocyte-derived particles into TF-sparse platelets, resulting in TF-
harbouring platelets. These activated platelets are hypothetically capable to provide all
factors of haemostasis [97]. Nagy et al. provided further evidence on the presence of MPs
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in patients undergone percutaneous coronary intervention and associated MP production
with increased stent restenosis [98]. Binding to resting cells can cause activation, as
well as membrane fusion of MPs and recipient cells. Activated neutrophils are able to
produce vesicles rich in Macrophage antigen-1, which can further activate still resting
platelets. TF is considered as a key factor of coagulation, the binding of TF to factor
VIIa can start the whole haemostasis cascade, therefore TF bearing MPs may play
pivotal role [99]. Also, endothelial MPs harbour ultra large VWF molecules, able to
stabilise aggregates [100]. Hrachovinova et al. assessed the eect of P-selectin in an in
vitro model. According to their data, the production of TF positive MPs is increased
in a dose dependent manner in the presence of P-selectin [101]. The importance of
MPs in coagulation is emphasised by the Scott syndrome, a rare congenital disease
characterised by the inability to rearrange platelet membrane components, resulting
in bleeding disorder [102]. According to the observation of Koppler and Gasser, MPs
released in early phases of inammation express inhibitory eects through transforming
growth factor beta-1, IL-10 and attenuation of IL-8 and tumor TNF- release, but have
pro-inammatory function later. This pro-inammatory state is maintained by CCR3,
CCR4 delivery and IL-6 release stimulation. Also, abundant broblast-derived vesicle
numbers were observed in arthritis patients. These particles induced matrix metallopro-
teinase (zinc-dependent, extracellular matrix endoproteases) release in arthritis patients
[103{105]. Matrix metalloproteinases are responsible for neovascularisation, but may
excert deleterious eect in septic patients [106]. MPs also contribute to vascular tone
dysfunction, as besides procoagulant attributes, PMPs may bear superoxide anion and
NADPH oxidase, able to induce stress response in endothelial and smooth muscle cells.
In experimental settings reactive nitrogen species were also observed in MPs, which
could modulate nitrogen oxide pathways in smooth muscle cells, impairing response to
vasoconstrictors. Mortaza et al. observed hypotension in rats, induced by pooled MPs
of septic rats (coecal ligature and puncture model), while control rat MPs were not
eective [107{110], but sporadic data support the hypothetical eect of MPs on heart
muscle contractility too. RANTES transfered to endothelial cells by PMPs help in the
recuritment of leukocytes (mostly monocytes) and diapedesis [111].
Protective role of MPs and their possible role in cellular "waste-management" was
demonstrated by Abid-Hussein et al. They found caspase-3 in vesicles released from vi-
able endothelial cells, while the inhibition of caspase-3 containing vesicle release resulted
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in subsequent cellular apoptosis. This nding suggests the pivotal role of vesicles in cell
survival following stress [112, 113]. Others found, that cells may release chemother-
apeutics, oxidised lipid compounds, drugs into the environment via vesicle shedding.
The exchange of nucleic acids between cells was also found in eukaryotes. Valadi et
al. showed that exosomes may contain mRNA or microRNA sequences. In this set of
experiments, mouse exosomes transferred successfully genetic material into human mast
cells, resulting in foreign protein expression [114]. Increased microparticle levels from
dierent bodily uids were reported in a large variety of diseases, but the exact role of
vesicle formation and presence is still not completely elucidated [91].
The above description of various pathways involved in MP production emphasise the
place of MPs in the crosstalk of inammation and coagulation, two major players of
sepsis pathophysiology. Considering the above discussed pathophysiology of sepsis and
microparticles, one may not wonder on the growing evidence regarding the controver-
sial, most likely deleterious eect of microparticles originating from sepsis-activated or
damaged cells [115].
Aims
1. Platelet aggregation in severe sepsis, to elucidate our hypothesis whether
microvascular ow deterioration can be a result of increased platelet aggregability:
 We aimed to evaluate the platelet aggregation alteration characteristics in
severe sepsis.
 We tried to assess the connection between reduced platelet count and mea-
surable platelet function in severe sepsis.
 We also aimed to assess the role of spontaneous platelet aggregation in severe
septic patients.
2. Microparticle studies in severe sepsis, as microparticles are mainly of platelet
or megakaryocyte origin in the blood and other sepsis-aected cell lines of the
circulation are also producing microparticles via activation and apoptosis, we
aimed to follow the microparticle prole in severe septic patients:
 We assessed the eect of dierent infectious agents on microparticle charac-
teristics.
 We aimed to provide further data regarding elevated microparticle levels in
septic patients.
 We evaluated the connection between developed sepsis-related organ failures
and microparticle levels.
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Patients and Methods
3.1 Patients
Recently diagnosed severe septic patients were enrolled from our multidisciplinary uni-
versity intensive care unit of the Department of Anaesthesiology and Intensive Therapy,
University of Pecs. Our studies were carried out in accordance with the ethical guidelines
of the 2003 Declaration of Helsinki and we obtained the permission of the Regional
Research Ethical Committee of University of Pecs (Ethical Committee reference num-
bers: 2406/2005 and 4234/2011). All patients provided a written informed consent
following detailed information regarding the study protocol and blood sampling. In case
of a consciousness disorder we obtained consent from the next of kin as per national
law. Our inclusion criteria were recently discovered severe sepsis (within 24 hours)
with two or more sepsis-related organ dysfunctions. Criteria for sepsis included: fever
(38C) or hypothermia (36C), tachycardia (90/min), tachypnoea, altered state
of consciousness, positive uid imbalance, hyperglycaemia, leukocyte count ( 12000
cell/µl or  4000 cell/µl), elevated C-reactive protein (CRP)(10mg=l), serum PCT
(PCT) level (2 ng=ml, and 5 ng=ml in the fungal MP study). In our platelet aggregation
study patients in moribund state or with any kind of haematological baseline disease
such as myeloproliferative disorders like lymphoma or leukaemia were excluded. For MP
measurements we extended our exclusion criteria, with certain known factors which can
signicantly alter MP amounts. Besides criteria addressed for the platelet study, the
following were introduced: cytostatic treatment in the last 30 days, high dose prolonged
steroid medication, patients with disseminated intravascular coagulation score 5 [116],
drugs known to alter platelet functions (i.e. acetylsalicylic acid), platelet transfusion
during the study period.
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We aimed to follow our patients until the 5th study day, or death during research period.
In case of death, patient data collected until the last platelet aggregometry or ow
cytometry measurement was assessed. If the patient or family withdraw consent we
did not used collected patient data. The diagnostic and treatment procedures of severe
sepsis were conducted by strictly following the most recent SSC guidelines (2005 and
2008 guidelines for the platelets and 2008 guidelines for the MP studies) in both study
and non-study patients [38, 117]. As detailed in before, sepsis therapy included: uid
resuscitation with crystalloids and colloids, early broad spectrum antibiotic treatment
(most commonly carbapenems with or without aminoglycosides), in case of haemody-
namic shock norepinephrine with or without dobutamine, for control of glucose levels
controlled infusion of human insulin, in oliguria or anuria furosemide with haemodialysis,
stress ulcer prophylaxis with pantoprazole or famotidine, thrombosis prophylaxis with
enoxaparine or fraxiparine, morphine and propofol were used for analgesia and sedation
respectively during mechanical ventilation at appropriate doses. No patient received
drotrecogin alfa or antiplatelet drugs. Laboratory parameters including C-reactive
protein, PCT, lactate concentration, blood cell count, electrolyte concentrations, blood
gas parameters and organ function specic parameters were registered. Laboratory
measurements were carried out in the Department of Laboratory Medicine, University
of Pecs. To follow-up the clinical status of severe septic patients, MODS and SOFA
scores were calculated every single day during the whole study period and Simplied
Acute Physiology Score II was calculated 24 hours following admission [4, 5, 118]. For the
assessment of various organ failures we used the reference values of the currently accepted
clinical guidelines, including the results of the RIFLE study (criteria summarised in
Table 1.2), as well as the SSC and our local laboratory reference values [29, 38]. All
data regarding organ dysfunctions were reassessed upon blood collection.
3.2 Platelet aggregation in severe sepsis
3.2.1 Blood sample collection
Arterial, 3  2:7ml Na3-citrate (0:129mmol) anticoagulated blood was gathered from
our patients for platelet aggregation studies. Blood samples were collected daily from
our patients once upon admission (1st day) and once for the following four consecutive
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days. Venous blood samples from antecubital venipuncture with a 21 gauge needle were
collected from 30 healthy controls. We avoided arterial blood sampling from control
volunteers due to possible bleeding complications. Furthermore, a pilot study showed
that platelet aggregation of venous and arterial blood is signicantly not dierent [119].
3.2.2 Platelet light transmission aggregometry
Light transmission ex vivo aggregometry was described by Born in the 60's and became a
wide used method for platelet aggregation and aggregation inhibition studies [120]. Our
measurements were carried out using the Carat TX4 (Carat Diagnostics Ltd., Budapest,
Hungary) 4-channel light transmission aggregometer. The instrument trans-illuminate
test samples with infrared spectrum light, registering the intensity decrease because of
scattered light. A platelet poor plasma sample is used to calibrate the equipment and
determine the minimum optical density of the measured sample (maximum aggregation).
Following, 4 platelet rich samples can be tested simultaneously. The equipment contin-
uously registers optical density changes during measurement. In platelet aggregation
studies, ADP is used in a wide concentration range of 1   10 µmol. Adrenaline (ADR)
is used in 5  10 µmol doses, but according to the literature is not a completely reliable
inducer. Nonsteroid anti-inammatory drugs, antihistamines, antibiotics and many
other compounds may alter platelet reaction to adrenaline. One of the most eective
classical inducers, collagen is usually used in 1   5 µg=ml concentration and produce a
two-wave aggregation. The rst wave represents the adhesion and early activation of
platelets on collagen bres, while the second phase (after an about 1 minute lag phase) is
the actual aggregation [121]. As dierent inducers acts on their own receptors, we were
able to determine the activity of various aggregation pathways. As formerly mentioned,
ADP-induced platelets are activated through P2Y1 and P2Y12 receptors, while ADR
acts on platelet 2a receptors. COL acts via dierent GP receptors, namely: GPIb
and GPIIb-IIIa (both in high shear condition via VWF), GPIa-IIa and GPVI (in low
shear-stress conditions). According to our knowledge, 0.9% NaCl solution (SAL) itself
is not able to induce platelet aggregation [122].
Blood samples were centrifuged with 150  g, 5 minutes and platelet rich plasma
was separated into four test cuvettes (450 µl each). The remaining blood sample was
centrifuged for further 10 minutes with 2500  g to obtain platelet poor plasma (500 µl)
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Figure 3.1: An illustration of analysed normal induced platelet aggregation results
using the Carat TX4 aggregometer (Abbreviations used: ADR: adrenaline, ADP:
adenosine-diphosphate, COL: collagen).
for minimum optical density determination. During aggregometry, agonists and saline
were introduced separately into platelet rich plasma samples. We used 50 µl of SAL
to measure the spontaneous and the in the same nal volume 10 µmol ADP, 2 µg=ml
collagen (COL), 10 µmol ADR (Theracont TA-3 inductor kit, Carat Diagnostics Ltd.)
to evaluate the inducible aggregation. We assumed spontaneous platelet aggregation to
be higher than 10%. Our opinion suggests that 1-3% aggregation could be an artifact.
If the spontaneous aggregation is higher and consecutive in the series of measurements
in one patient, it has to be analysed as an objective result. This is why we chose the
10% value as a reference due to the absence of data from literature. The inducible
platelet aggregation was chosen  60% measured by the TX4 aggregometer. This value
was veried in a study which was performed in our University [123]. We formed a low
platelet count a normal platelet count group, based on the inclusion blood platelet count
of our severe septic patients and thrombocytopenia criteria of the SSC2008 [38].
3.2.3 Statistical analysis
In our rst study statistical analysis was carried out using SPSS 17 for Windows software.
Data are presented with median and interquartiles. Kruskal-Wallis-test was used with
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p<0.05 considered signicant. The number of patients required was calculated by power
analysis according to spontaneous and non-spontaneous platelet aggregation results from
our previous pilot studies performed on similar population. Therefore, with type I a =
5% and type II (power) of 90% we needed 40 patients at minimum.
3.3 Microparticle studies in severe septic patients
3.3.1 Blood sample collection
For MP studies, additional 2  2:7ml arterial blood samples were drawn on inclusion
(1st), and on the 3rd and 5th days with a 21 gauge cannula into a closed system blood
sampling tube with Na3-citrate (0:129mmol) as anticoagulant. Samples were processed
within maximum 30 minutes following collection. Volunteers provided blood for ow
cytometry measurements on one occasion. Blood collection from volunteers was carried
out through antecubital vein puncture without strangulation with a 21 gauge needle into
closed system and processed the same way as patient samples. Upon blood collection,
the rst 3ml arterial or venous blood was discarded to prevent mixture with infusion
uids or venipuncture induced activated thrombin. Both microparticle studies are based
on the same patient pool, our second analysis took place after patient data reassessment
and inclusion of new patients in our study. Twenty, age and gender matched apparently
healthy volunteers were invited to determine the baseline values of our measurements.
Patient exclusion criteria were also applied for our volunteer group.
3.3.2 Microparticle isolation and ow cytometry measurement
Flow cytometry is based on the measurement of scattered and absorbed-emitted light.
With the utilisation of vacuum pumps, the cytometer takes small amounts of usually
diluted samples (below 1ml total volume) and appropriate sheath uid in a stabilised
ow rate. Sample material is centred using hydrodynamic focusing, in a ow cell (sheath
uid focusing) or nozzle tip (free air focusing). Hydrodynamic focusing is achieved by
two parallel lamellar uid streams. The outer sheath uid stream and the narrowing
part of the ow cell cause the same "narrowing" of the sample uid, focusing one thin
uid line in the centre of the laser stream. Ideally, the centralised sample material
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contains only 1 cell (or particle) in line with the focused exciting laser beam. In case
of the Beckman-Coulter Cytomics FC 500 cytometer (Beckman-Coulter Hungary Ltd.,
Budapest, Hungary) a standard argon ion laser (488 nm, 20mW) is used for light scatter
and colour cytometry measurements, while an additional 637 nm (20mW) HeNe or
diode laser can be installed for 5 colour cytometry. Forward scatter detector measures
diracted light, while side-scatter detector measures refracted and reected photons.
Forward-scatter is proportional to the size, while side-scatter is proportional to the
granularity and internal complexity of the illuminated event (according to Snell's law).
The forward scatter detector of the FC 500 has a nominal size limit of 500 nm, therefore
particles smaller than this cannot be reliably distinguished from light and electrical
noise. Fluorochromes are excited by the primary (Ar-ion) or secondary (HeNe or diode)
laser, elevating an electron of the uorochrome to a higher energy state. Without the
energy of the exciting light, the electron is unstable in the new state. Inside the new
elevated energy state, it releases small amounts of energy in form of heat to reach the
lowest energy of the excited state. Following it returns to its ground level, emitting
a characteristic photon, which has dierent frequency because of the released heat.
The emitted light is ltered through low- and high- wavelength pass optical lters and
dichotomous mirrors to direct ltered light into photodetectors [124]. The evolving
technical background of ow cytometry and the introduction of new cytometers boosted
MP studies signicantly. New cytometers are able to dissociate MP sized events from
background noise. Our FC 500 equipment is able to measure events as small as 500 nm
in forward and >200 nm in side-scatter mode (according to instrument description).
Regrettably, no standardised method was available during the planning phase of our
studies, but the International Society of Thrombosis and Haemostasis introduced a
standardisation recommendation, which nowadays considered as a gold standard of
measurements [125]. Our methods largely overlap with the presented recommendations,
although we used dierent (custom made) beads for instrument setup.
3.3.2.1 Microparticle isolation and staining protocol
Flow cytometry measurements were carried out from fresh samples. Following collection,
blood was centrifuged at 800g for 20 minutes at room temperature to obtain platelet-
rich plasma. The 1:5ml supernatant was transferred into a new test tube and centrifuged
at 1500g for further 20 minutes to obtain platelet-poor plasma. The 1ml volume of
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platelet-poor plasma was further centrifuged at 1500g 20 minutes in a new polystyrene
tube to obtain cell-free plasma. The top 500 µl of cell-free plasma was transferred into
an Eppendorf tube and pelleted at 18000g for 10 minutes. The supernatant was
carefully removed leaving 250 µl of MP rich plasma and pellet at the bottom of the
Eppendorf tube. MPs were suspended with gentle vortexing over 20 seconds in 1.0
ml Apo-binding buer (10mmol=l HEPES, 5mmol=l KCl, 1mmol=l MgCl2, 136mmol=l
NaCl, pH=7.4. HEPES was obtained from Sigma-Aldrich Ltd., Budapest, Hungary,
other analytical grade reagents were obtained from Reanal Ltd., Budapest, Hungary)
without CaCl2. All antibodies and annexin V were titrated in preliminary experiments
to determine the optimal labelling concentrations. Labelling concentrations were dened
by antibody staining of samples and sample-free buers in the presence or absence of
CaCl2. Labelling was considered optimal if CaCl2 labelled sample measurement events
were clearly distinguishable from background, CaCl2 free staining, as well as from isotype
controls. Isotype controls, uorescein isothiocyanate, cychrome 5 or phycoerythrin
conjugated mouse immunoglobulin G1 were used (Becton Dickinson Hungary Ltd.,
Kornye, Hungary).
Table 3.1: Specicity, clone and manufacturer of antibodies used for microparticle
labelling. Abbreviations used: Cy5: Cychrome5, PerCP: Peridinin chlorophyll protein,
FITC: uorescent isothiocyanate, PE: phycoerythrin, Ig: immonuglobulin.
Antibody Fluorescent dye Clone Manufacturer
CD41 Cy5 HIP8
CD42a PerCP Beb1
PAC1 FITC PAC1
annexin V FITC, Cy5 -
mouse IgG1 FITC,Cy5, PE X40
Becton Dickinson
CD61 FITC RUU-PL7F12 Beckman-Coulter
Fluorescein isothiocyanate or cychrome 5 labelled annexin V (Becton Dickinson) in
12 µg=ml or 8 µg=ml concentrations respectively were used to identify MPs. Constitu-
tively expressed platelet brinogen receptor subunits, GPIIb-IIIa were measured by the
CD41 and CD61 antibodies respectively. Activated platelet marker, brinogen binding
form of 2b3 was assessed by the PAC1 antibody. Platelet adhesion receptor GPIb-
V-IX has been tested with anti-IX (CD42a) labelling (Table 3.1).
For sample labelling, 10 µl MP in Ca2+ free buer was incubated in 100 µl Apo-binding
buer supplemented with 2:5mmol=l CaCl2 with total 10 µl antibody, previously diluted
to optimal labelling concentration. Staining was incubated for 30 minutes at room
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temperature in dark chamber.
Flow cytometry measurements and data analysis were performed on our FC 500 ow
cytometer with CXP software (Figure 3.2). The MP gate was dened in order to
distinguish the true events from electronic noise and background, using 0:3 µm, 0:5 µm
and 1:0 µm FITC labelled microbeads (a kind gift of SoftFlow Ltd., Pecs, Hungary). Side
scatter, forward scatter and uorescence channels were set in logarithmic scale. MP size
gate was determined between 0:5 µm and 1:0 µm size range. Events in the MP gate
were further discriminated by labelling with annexin V. MPs were dened as annexin
V positive events in the MP gate with uorescence intensity above the isotype control.
Figure 3.3 illustrates our cytometry gating strategy [126]. Subgure A illustrates the
MP size gate and counting beads for particle number estimation. Figure 3.3B shows
annexin V staining in the presence of ethylenediaminetetraacetic-acid, to determine
background of annexin V. 3.3C is the actual annexin V stained sample, while 3.3D is
the isotype control for uorescein isothiocyanate and 3.3E shows the PAC1-FITC stained
vesicles. For determination of the MP number, known concentration (1 105 =ml) of
3 µm diameter microbeads (Becton Dickinson) was used. Microparticle measurements
were carried out in the Department of Laboratory Medicine, University of Pecs. Intra-
run variation coecient range of our complete isolation and ow cytometry method,
determined by total 25 measurements from 5 dierent controls is 15.4-19.2%.
Figure 3.2: The Beckman-Coulter Cytomics FC 500 ow cytometer.
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Figure 3.3: Flow cytometry gating strategy used for microparticle measurements.
Abbreviations used: EDTA: ethylenediaminetetraacetic-acid, FITC: fulorescent isoth-
iocyanate, Cy5: Cychrome5.
3.3.2.2 Microparticle measurement protocol controls
MPs isolated after stimulation of pooled platelet rich plasma from 5 healthy volunteers
without platelet function altering medication with calcium ionophore A23186 (Sigma-
Aldrich Ltd., 25 µmol=ml, 37C, 10 minutes) were used as positive controls. 200 uL of
pooled platelet rich plasma was mixed with the above mentioned A23186 concentration
and incubated on room temperature for 30 minutes. MP isolation was continued from
the 2nd centrifugation step accordingly. MPs stained with annexin V in presence of 2.5
mmol=l ethylenediaminetetraacetic acid were measured for negative controls.
3.3.3 Microbiological diagnosis and treatment of patients of the fungal
infection - microparticles study
For the diagnosis of the microbial agent(s) in sepsis, haemocultures, urine samples and
bronchial lavage uids were gathered. Haemocultures were obtained through a fresh
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vein or arterial puncture, prior to empirical antimicrobial medication, into BACTECTM
haemoculture asks (Becton Dickinson) from patients showing the signs of systemic
inammation response syndrome without recent microbiological results. Further mi-
crobiological sampling was carried out in case of continuous or elevated fever with
shivering or overall patient clinical status deterioration including continuously elevated
or increasing C-reactive protein and PCT results following the proper antimicrobial
treatment. Microbiological identication was performed in the Department of Medical
Microbiology and Immunology, University of Pecs. Empirical antibiotic therapy was
started following microbiological sampling. The applied therapy generally consisted of
carbapenems, respiratory uoroquinolones, metronidazole and second or third genera-
tion cephalosporins. The selection of antibiotics was based on the clinical background
and possible site of infection. Empirical antifungal therapy (mainly uconazole) was
administered in case of positive patient history for diabetes, immunocompromised state
(i.e. tumours or steroid treatment), long-term antibiotic treatment, progressive sepsis
without or with only slight PCT elevation accompanied by constant fever with shivers.
Patients in our study were designated as fungal septic in case of positive blood culture
results for fungal infection accompanied by the above mentioned clinical signs, following
proper antibacterial treatment during our study period. Based on these criteria a fungal
septic and a non-fungal septic group were formed.
3.3.4 Statistical analysis
For statistical analysis of our MP study data SPSS 19 for Windows software was used.
For the comparison of septic and control patients Mann-Whitney U-test was carried
out. For subgroup analysis of severe septic patients ANOVA test was used, corrected
for multiple analysis. Correlation analysis was carried out using Spearman's rho. In
calculations p<0.05 was considered signicant.
Results
4.1 Platelet aggregation in severe sepsis
Forty-ve patients were included in our platelet aggregation study during the study
period of 2005 June - 2008 October. Main demographical data, MODS and SOFA scores
calculated on the rst, third and fth admission day and sepsis-induced organ failures
(day 1) of our study population are discussed in Table 4.1. We found no signicant
change of clinical scores in this patient population during our study period. As seen
from our microbiological summary, only 36 of 45 patients had proved infection, while
other sepsis criteria were met. Gram-negative bacteria were present in 26 patients, while
Gram-positive infection was detected in 20 patients. The total number of infections
is above our patient group size, indicating that some patients suered from multiple
infections. Renal function impairment (n=38), hypotension (n=35) and respiratory
insuciency (n=32) combined were the leading causes of patient admittance and in-
clusion. Besides the use of low molecular weight heparins (mainly enoxaparine) and
corticosteroids in case of indication, patients did not received medications known to
alter platelet function.
The evaluation of platelet aggregation in septic patients compared to healthy controls
revealed a signicant deterioration in the inducible aggregation among septic patients.
The ADP, ADR and COL induced function measurements resulted in signicantly
lower levels for all the ve study days (p<0.05) while SAL based aggregation showed a
signicant increase in the platelet function of septic patients (Figure 4.1, p<0.001). A
slight increase is notable in ADP and ADR aggregation throughout our study period,
but this increase does not reach control levels. COL aggregation was continuously low
in septic patients. SAL aggregation was continuously elevated in severe septic patients
34
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Table 4.1: Demographical, microbial and sepsis-related data of our platelet study
patients and controls, data presented as median and interquartiles. Abbreviations:
MODS: Multiple Organ Dysfunction Score, SOFA: Sequential Organ-Failure Assess-
ment.
Patients (n=45) Controls (n=30)
Age 63 (51 - 71) 52 (49 - 67)
Gender (male / female) 29 / 16 19 / 11
MODS score (day: 1, 3, 5) 8 (6 - 10), 7 (5 - 9), 6 (3 - 8)
SOFA score (day: 1, 3, 5) 9 (7 - 12), 8 (5 - 12), 6 (5 - 10)
Gram-negative infection 26
Gram-positive infection 20
Fungal infection 11
Patients with proved infections 36
Renal failure 38
Arterial hypotension 35
Respiratory insuciency 32
Altered mental status 27
Hepatic disorder 18
Bone marrow insuciency 8
compared to controls, peaking on the 3rd measurement day. Statistical comparison of
the 1st and 5th day data shows no signicant dierence. On admission 19 patients were
in the low platelet count range and 26 patients formed the normal platelet count group
according to the thrombocytopenia criteria. We did not found signicant dierence
in clinical and demographical data of these patient groups. ADP induced platelet
aggregation was signicantly deteriorated in patients with low platelet count in all 5
days (p<0.05), with an observable (but not signicant) increase of aggregation in the
normal platelet count group. ADR caused aggregations were lower in the 2nd, 3rd,
4th and 5th consecutive day (p<0.05) in the low platelet count group, with the same
notable elevation of aggregation results in the normal platelet group. COL induced
aggregation was signicantly lower on the 1st, 2nd, 3rd days following admission (p<0.05).
COL aggregation of both groups did not changed notably during our study period.
There was no dierence between the two groups based on the saline aggregation, both
groups kept the characteristic increase towards the 3rd measurement day (Figure 4.2).
Compared to our control group most aggregations measured in the normal platelet group
were signicantly lower than the control results with the exception of the adrenaline
inducible aggregation on the 3rd, 4th, 5th days and ADP induced aggregation on the 5th
day (p<0.05, data not shown). The low platelet group had signicantly deteriorated
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Figure 4.1: Platelet aggregation in severe septic patients and controls. Clear
represents control patient data, shaded boxes represents severe septic patient data.
*:p<0.05 between measurement points. Abbreviations: ADP: adenosine-di-phosphate,
ADR: adrenaline, COL: collagen, SAL: 0.9% NaCl solution.
aggregation levels with all inductors in all cases (p<0.001, data not shown) compared
to controls.
Fourteen patients deceased during our study and 31 patients built up the survival group.
Non-survivors showed no signicant deterioration in platelet count (p>0.05, data not
shown). All induced and saline aggregation measurement results, when compared to
survivors were not signicantly dierent in non-survivors (Figure 4.3). ADP aggregation
showed a slight decrease on the 2nd study day, but increased slightly in our study period.
ADR aggregation increased throughout our study period in both groups, while COL
aggregation does not shows elevation. SAL aggregation results represents the increase
towards the 3rd study day. In the survivor group we found four patients with notable
aggregation levels (50%) during the saline based aggregation tests. The spontaneous
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Figure 4.2: Platelet aggregation in severe septic patients with low (n=19) and normal
(n=26) platelet count. Light shaded boxes represents normal platelet count patient
data, dark shaded boxes represents low platelet count data. Data presented as median
and interquartiles. *:p<0.05 between measurement points. Abbreviations: ADP:
adenosine-di-phosphate, ADR: adrenaline, COL: collagen, SAL: 0.9% NaCl solution,
PLT: platelet.
aggregation group (14 patients) revealed a non-signicant dierence in platelet counts
compared to the non-spontaneous aggregation group. The non-spontaneous aggregation
group showed a signicantly higher, but constantly decreasing PCT levels on the 1st, 3rd,
4th consecutive days. Lactate levels were also non-signicantly lower in the spontaneous
aggregative patients during our study (Figure 4.4). Also, we assessed if the presence
of corticosteroids in patient therapy has any eect on platelet aggregation, but did not
found signicant dierence in inducible or spontaneous aggregation results. Of all 36
patients with proven infections, only 7 patients presented Gram-negative bacteria only.
According to our analysis, the presence of Gram-negative bacteria did not contribute to
spontaneous aggregation signicantly, although patients with spontaneous aggregation
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Figure 4.3: Platelet aggregation in survivor (n=14) and non-survivor (n=31) severe
septic patients. White boxes represents survival patient data, grey boxes represent non-
survival patient data. Abbreviations: ADP: adenosine-di-phosphate, ADR: adrenaline,
COL: collagen, SAL: 0.9% NaCl solution.
and Gram-negative infection showed signicantly increased aggregation levels compared
to patients without Gram-negative bacteria.
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Figure 4.4: Procalcitonin, lactate and platelet count comparison of the spontaneous
(n=14) and non-spontaneous (n=31) platelet aggregation groups. *:p<0.05 between
measurement points.
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4.2 Microparticle studies in severe septic patients
4.2.1 The eect of mixed fungal sepsis on microparticle prole
During our rst microparticle study 57 patients were eligible according to our inclusion
criteria, but only 33 patients gave an informed consent. Eight patients refused participa-
tion following detailed information about our study. 16 patients were excluded based on
our criteria, after the reassessment of patient history (mainly because of platelet inhibitor
use or prolonged steroid therapy). Our MP study took place from 2008 January, the
rst study assessment was carried out in 2010 January, the second assessment was done
in 2011 December.
Basic patient characteristics and clinical data including clinical status scores are de-
scribed in Table 4.2. Age, survival data, laboratory markers on admission and calculated
clinical scores did not dier signicantly between the mixed fungal and non-fungal
septic patient groups. Also, age and gender characteristics of the volunteer group (n
= 20, median age: 60 (56-65) years, 1:1 gender ratio) showed non-signicant dierence
compared to the septic, mixed fungal and non-fungal groups. All enrolled severe septic
patients presented with elevated PCT and CRP levels. Clinical data did not dier
in mixed fungal and non-fungal septic patients. Also, clinical scores did not show
signicant change during our study period. The most common organ dysfunctions
developing in our patients were: kidney dysfunction (oliguria or anuria), haemodynamic
shock, consciousness disorder and respiratory failure. A large portion of bacterial and
fungal infections identied in our patients were mixed bacterial or mixed bacterial-fungal
infections. Six patients comprised the mixed fungal septic group and 27 patients were
in the non-fungal septic group. Microbiological identication proved C. albicans species
in all six fungal septic patients. Two patients of the mixed fungal septic group and 5
from the non-fungal septic group died during the study period.
Upon admission total annexin V positive MPs and CD41 positive PMPs were elevated
in both the mixed fungal and in the non-fungal septic group compared to our volunteer
group. Most MPs (above 60% average) were positive for constitutive platelet antigen
CD41, therefore recognised as PMPs. While mixed fungal septic patients showed ele-
vated annexin V positive MP number throughout our study with a slight decrease on
the 3rd day, the non-fungal septic patients showed constantly decreasing MP numbers
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Table 4.2: Demographical and illness related data of our rst sepsis - microparticle
study. Data presented as median and interquartiles. Abbreviations used: S:
survivor, NS: non-survivor, PCT: procalcitonin, CRP: C-reactive protein, MODS:
Multiple Organ Dysfunction Score, SOFA: Sequential Organ-Failure Assessment, SAPS:
Simplied Acute Physiology Score.
All patients Non-fungal septic Mixed fungal sep-
tic
Demographic data:
Number of patients 33 27 6
Age (years) 63 (53 - 72) 65 (54 - 72) 63 (54 - 75)
Outcome (S / NS) 26 / 7 22 / 5 4 / 2
Gender
(male / female)
18 / 15 15 / 12 3 / 3
Clinical status:
PCT
(ng/ml, admission)
12.94
(5.11 - 69.805)
12.94
(5.11 - 70.39)
6.93
(4.89 - 65.91)
CRP
(mg/l, admission)
200.94
(122.85 - 71.75)
185.77
(123.56 - 270.5)
156.34
(89.03 - 241.5)
Lactate
(mmol/l, admission)
1.8
(1.3 - 3.32)
1.76
(1.29 - 2.55)
1.55
(1.12 - 2.04)
MODS
(1st, 3rd, 5th day)
8 (5 - 11),
7 (5 - 10),
6 (3 - 8)
7 (4 - 9),
7 (5 - 9),
6 (3 - 8)
7 (5 - 10),
7 (5 - 9),
4 (3 - 8)
SOFA
(1st, 3rd, 5th day)
9 (7 - 12),
8 (6 - 13),
7 (5 - 10)
8 (7 - 10),
8 (6 - 11),
7 (5 - 9)
7 (6 - 11),
8 (4 - 12),
5 (4 - 10)
SAPS II 50 (34 - 67) 49 (33 - 67) 50 (32 - 69)
Organ dysfunctions:
Kidney dysfunction 28 23 5
Respiratory failure 26 22 4
Haemodynamic insu. 25 20 5
Consciousness disorder 19 14 5
Hepatic disorder 11 8 3
Thrombocytopenia 8 7 1
Proved infections:
Gram-negative
(mixed)
25
(16)
Gram-positive
(mixed)
18
(17)
Fungal infections
(mixed)
6
(6)
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Figure 4.5: Annexin and platelet marker positive microparticles in mixed fungal
(n=6) and non-fungal (n=27) septic patients. *: p < 0.05, comparing septic patient
data
# # # # # #
Figure 4.6: Activated platelet-derived microparticles in mixed fungal (n=6) and non-
fungal (n=27) severe septic patients. #: p < 0.01, comparing septic patient data
during our study period. The elevation was signicant in mixed fungal compared to non-
fungal septic patients on the 1st study day (Figure 4.5 p<0.05). The CD41 positive PMP
numbers were decreasing until day 5 in non-fungal septic patients and were constantly
elevated in the mixed fungal septic group. The elevation was statistically signicant on
the 1st day (Figure 4.5 p<0.05). CD61 results were statistically identical to CD41 results
in all measurements (data not shown). While CD42a+ PMP numbers were negligible in
the non-fungal group and in controls, mixed fungal septic patients showed signicantly
elevated numbers in all measurements with a steep elevation until day 5 (Figure 4.6
p<0.05). Mixed fungal septic patients presented a wide range of CD42a+ particles.
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Figure 4.7: Receiver operator characteristics analysis of activated platelet markers in
severe sepsis. (AUCCD42a=0.857, AUCPAC1=0.897)
Although PAC1+ PMPs numbers showed a slight decrease and marked variety until
day 5 in fungal septic patients, this group of patients had signicantly elevated numbers
of PAC1 positive PMPs in the 1st and 5th study days compared to non-fungal septic
patients. Non-fungal patients had low numbers of PAC1 positive PMPs (Figure 4.6
p<0.05). Receiver operator characteristic curves (Figure 4.7) calculated on the presence
of mixed fungal sepsis in patients using all data of PAC1 and CD42a MP measurements,
revealed an area under the curve of 0.857 and 0.897 respectively. The evaluation of
dierent bacterial sources (Gram-negative or Gram-positive bacteria) in the non-fungal
septic group revealed no signicant dierences of PMPs from various bacterial infection
origins. Also, platelet counts in dierent groups (fungal, non-fungal or Gram-negative
and Gram-positive) did not diered signicantly throughout our study period.
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Table 4.3: Demographical and sepsis related parameters of patients from our second
microparticle study. Data presented as median and interquartiles
Septic patients Controls
Demographic data:
Total number 37 20
Gender (male / female) 20 / 17 10 / 10
Age 63 (53 - 72) 47 (38 - 73)
7 days mortality (S/NS) 8 / 29
28 days mortality (S/NS) 17 / 20
Calculated clinical scores:
MODS (1st, 3rd, 5th days) 8 (5 - 10), 7 (6 - 10), 6 (4 - 8)
SOFA (1st, 3rd, 5th days) 9 (7 - 11), 9 (7 - 10), 8 (5 - 9)
Specic markers on admission:
PCT (ng/ml) 10.00 (4.45 - 44.98)
CRP (mg/l) 185.77 (113.14 - 284.62)
Lactate (mmol/l) 1.90 (1.23 - 2.62)
D-Dimer (µg/l) 2342 (1043 - 4324)
No of organ dysfunctions: 4 (3 - 5) in all patients
Renal insuciency 30
Respiratory disorder 29
Haemodynamic impairment 28
Hepatic disorder 12
Thrombocytopenia 14
Impaired consciousness 21
No of approved infections:
Gram-positive 19
Gram-negative 27
Fungal infection 7
4.2.2 Organ dysfunction, outcome and microparticles
After patient data and ow cytometry result reassessment, we included data from 37
severe septic patients in our next study. Although we gathered data from almost 65
patients, based on the exclusion criteria and lack of informed consent or patient data
we were unable to include all patients. In this study we focused on sepsis outcome, the
presence of various organ dysfunctions and the connection with microparticle prole.
Summarised numbers of organ failures on inclusion accompanied by basic demographic
and sepsis oriented laboratory data gathered are listed in Table 4.3. To take underlying
baseline diseases into account, a new age and gender adapted control group was invited.
Most patients suered from renal disorder besides haemodynamic impairment on inclu-
sion; therefore we focused our data assessment on this organ dysfunction. The control
groups age and gender did not dier signicantly from the septic patient group. The
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measurement of microparticle numbers in severe septic patients compared to controls
revealed a signicant increase of annexin V and CD41 positive microparticles in severe
septic patients during the whole study period (Figure 4.8, p<0.001). CD42a positive
particles showed a constant elevation in severe septic patients (Figure 4.8, p<0.001).
We also found elevated PAC1 positive particle numbers in severe sepsis, but a steady
decrease is notable from day 1 towards day 5 (Figure 4.8, p<0.05). The presence of
CD41, CD42a, and PAC1 positive particles showed no correlation with actual platelet
numbers. According to our results, survivor and non-survivor patient results, assessing
7 days and 28 days mortality showed no signicant dierence in annexin V, or specic
marker positive MP results (data not shown, p>0.05). Our results showed, that actual
number of organ failures do not have a direct eect on total annexin V+ (Figure 4.8),
CD13+ or CD14+ microparticle count (data not shown). The assessment of the eect
of sepsis-related organ failures on microparticle numbers revealed, that patients with
acute sepsis-related renal injury on admission have signicantly dierent MP numbers
compared to patients without renal impairment. To concentrate our assessment on the
new onset renal injury in septic patients, we excluded 4 patients from the assessment of
sepsis-related renal injury; as according to patients' history, they suered from chronic,
renal function altering illnesses. Total annexin V positive, as well as CD41+ and
CD13+ particle numbers were signicantly elevated in patients with renal injury on
inclusion. Although patients presented a wide variety of total MP numbers, patients
with renal injury showed signicantly increased MP numbers on inclusion and a slight
decrease of MP numbers on day 3. Patients without renal injury had a continuous
elevation of MP numbers during our study period (Figure 4.9, p<0.05). Patients without
renal injury showed a steady non-signicant increase of CD41+ particles, while sepsis-
related renal injury patients had elevated CD41+ MP numbers on admission already.
Also, CD13 harbouring particles were signicantly elevated on admission in patients
with renal impairment (Figure 4.9, p<0.05) and patients without renal failure showed
elevating MP numbers. Summarised data from our study measurements showed, that
the presence of CD42a+ particles in patients with acute renal injury correlated negatively
with measured BUN and creatinine concentrations (respectively: p<0.05, r=-0.835,
r=-0.569). We carried out the same detailed assessment of other severe sepsis-related
organ dysfunctions (arterial hypotension despite of uid therapy, consciousness disorder,
respiratory insuciency, thrombocytopenia/blood marrow insuciency, liver function),
based on clinical assessment and laboratory data. Statistical analysis of these groups
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revealed that MP, particularly PMP numbers do not show signicant dierence in these
severe sepsis-related organ dysfunctions in our study setting (data not shown).
# # # # # #
# # # # * *
Figure 4.8: Microparticle count comparison of severe septic patients (n=37) and
controls (n=20). (#: p<0.01, *: p<0.05)
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Figure 4.9: Microparticle count comparison of severe septic patients with multiple
organ failure and presenting or without acute sepsis-related kidney injury. Subgure
4.9A represents MP numbers and number of organ dysfunctions of severe septic patients.
4.9B-D shows data from patients with or without acute kidney injury. (#: p<0.01, *:
p<0.05)
Discussion
Platelet count disorders and thrombocytopenia have been already observed in 33-45% of
septic patients, however the exact mechanism behind the development of sepsis-induced
thrombocytopenia requires further investigation [127, 128]. Sigurdsson et al. using
radioisotope-labelled autologous platelets provided evidence, that even though macro-
scopic pathology observation did not provided evidence of intravascular coagulation,
non-survivor septic patients had platelet sequestration in the intestinal vascular system
[129]. Also, Singer et al. showed platelet recruitment in terminal hepatic venules in
a caecal ligation and puncture murine sepsis model [130]. It is commonly accepted,
that platelets do not form aggregates in healthy individuals [131], while Eto et al.
presented aggregates containing less than 100 platelets in patients with acute coronary
syndrome using the high sensibility laser light scattering aggregometry method [132].
Also, patients with acute myocardial infarction have shown increased aggregation levels
which correlate with the size of the necrotic tissue [133]. The primary objective of our
rst study was to evaluate the alterations of inducible aggregation in severely septic
patients and determine its usefulness as a predictor of overall mortality. Former platelet
function tests utilising ow cytometry presented the loss of platelet function in patients
developing multiple organ dysfunction syndrome [134, 135]. Our data shows a signicant
deterioration in ADR, ADP, and COL inducible aggregation compared to the control
group but no change was observed during the 5-day period. Yaguchi et al. showed
a loss of inducible platelet aggregation in patients with severe sepsis in contrast with
other studies suggesting increased platelet function in trauma based septic shock patients
[136, 137]. In concordance with Yaguchi's ndings, our study found a similar decrease in
aggregation among severe septic patients. Interestingly, ow cytometry measurements
showed decreased PAC1 and brinogen binding in septic patients, while unchanged
CD62P avidity [136]. As resting platelets store CD62P in -granules, the presence
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of CD62P but lack of active 2b3 (measured by PAC1) may show unchanged platelet
activation, but loss of aggregation function. According to Lundhal et al. more "active"
platelets are activated and consumed in the early stage of sepsis therefore platelet
function should decrease during critical illness [134]. Yaguchi formerly described, that
patients with lower platelet count have more decreased inducible aggregation. Our data
support this nding, as patients with low platelet count showed signicantly deteriorated
aggregation response to inducers. In our data survivor and non-survivor patient groups
did not show signicantly dierent inducible or spontaneous aggregation. As platelet
sequestration may develop in the circulation of severe septic patients, we think that
this result can not disprove or support the theory of Eisen, but prove that this platelet
aggregation measurement could not be recommended for mortality prediction. Until
now, studies have not reected the use of saline as an alternative to inductors used for
the measurement of spontaneous aggregation in severely septic patients, although saline
was used to assess spontaneous aggregation in former studies [138, 139]. Using saline as
"inducer" in Born's optical method showed signicant aggregate formation in a group
of severely septic patients compared to healthy controls. There is inconsistent data
on the eect of LPS and Gram-negative bacteria on platelet activation, secretion and
aggregation [140{142]. According to our data the presence of Gram-negative bacteria
was not the sole cause of spontaneous aggregation, although patients with spontaneous
aggregation and Gram-negative infections showed increased aggregation levels. There is
a growing evidence of possible benecial eect of anti-platelet therapy in the early phase
severe sepsis. The review of Eisen discuss pathophysiological and pharmaceutical eects
of acetylsalicylic acid therapy and conclude that platelet inhibition may be benecial for
patients [143]. Increased PCT levels in the non-spontaneous group hypothesise that
members of this group may had a more severe state compared to the spontaneous
group. Also, the cross-link between inammation and haemostasis support the theory
of marked platelet activation in severe sepsis [22, 25, 35]. Lactate levels did not dier
signicantly in the spontaneous groups. Although we are aware of the low sensitivity and
specicity of lactate levels, we hypothesise that microcirculation and tissue oxygenisation
was not signicantly dierent in both groups [144]. The lack of lactate dierence
and steady decrease in both groups may rise from appropriate uid and supportive
therapy. A former study on rabbit platelets presented a dose-dependent inhibitory
potential of methylprednisolone on inducible aggregation [145]. In patients who received
corticosteroids during treatment, we did not nd signicant variations either in the
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inducible platelet aggregation values or in spontaneous aggregation. Homogeneously,
all patients received low molecular weight heparin treatment which could also slightly
decrease platelet aggregation but we analysed and focused on the changes of the inducible
aggregation [146]. Due to ethical concerns, the eect of other recommended and regular
treatments (vasopressor and inotropic agents, infusions for uid replacement, insulin,
stress ulcer prophylaxis, analgesics, sedatives, antibiotics etc.) were not investigated in
drug free patient subgroups.
Besides haemostasis and particularly aggregation, the role of platelets in early host
defence and inammation is long debated. Yeaman et al. discussed platelet reactions to
endothelial injury and for the presence of microbial agents extensively [147]. Bacteria
and fungi are known to activate platelets, following activation platelets can act directly
by adhering to the endothelial wall or to the pathogen, forming aggregates. Also,
antimicrobial proteins are released from platelets. These proteins, like thrombocidins
are highly eective against certain bacterial and fungal strains while others successfully
developed resistance against them. The increase of platelet activation markers and
adhesive platelet markers on PMP surfaces may indicate platelets' contribution in early
host defence [148{150]. Besides haemostasis and particularly aggregation, the role
of platelets in early host defence and inammation is long debated. Yeaman et al.
discussed platelet reactions to endothelial injury and for the presence of microbial agents
extensively [147]. Bacteria and fungi are known to activate platelets, following activation
platelets can act directly by adhering to the endothelial wall or to the pathogen, forming
aggregates. Also, antimicrobial proteins are released from platelets. These proteins,
like thrombocidins are highly eective against certain bacterial and fungal strains while
others successfully developed resistance against them. The increase of platelet activation
markers and adhesive platelet markers on PMP surfaces may indicate platelets' contri-
bution in early host defence [148{150]. Formerly, there was a notable inconsistency
in MP data from severe septic patients. Joop et al. reported the decrease of MPs
from various origins (platelet, erythrocyte, endothelial cells, granulocytes) in multiple
organ dysfunction and sepsis, compared to healthy controls [151], while in another paper
Nieuwland et al., found increased vesicle numbers in meningococcal sepsis [152]. Our
data support the model of increased numbers of PMPs compared to volunteers in sepsis.
We have shown, that compared to severe bacterial sepsis, severe sepsis with mixed
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fungal infection contributes to more increased PMP levels in our multidisciplinary ICU
setting. Although, formerly fungal sepsis was considered rare and according to current
data fungi contributes only about 5% as a main pathogen of all infections, a current
review by Lepak and Andes presented a 2-fold increase of Candida incidence from 1979
to 2000 with the estimated incidence of 25-30/100000 persons annually [153]. Most
fungal infections are present as a superinfection or develop following proper antibacterial
treatment [153]. In addition, a large portion of patients, who suer from prolonged sepsis
characterised by protein wasting, are prone to further infections, which combined further
deteriorate overall outcome. Commonly used culturing methods are considered rather
slow and not completely reliable, but these approaches support appropriate antimicrobial
selection. The assessment of a conventional automated haemoculture system found,
that opposed to current guidelines in sepsis (SSC2008, [38]), at least 3 cultures and
24 hours incubation time is necessary to reach an optimal infection detection rate of
95% [154]. According to the review of Annane et al. and Lepak et al., blood cultures
may require more than 6 hours, while the detection rate could be as low as 30% [11,
153]. The identication of Candida fungal strains may need up to 5 days, while the
detection rate may not increase above 67% [154]. Also, a recent study showed that
most patients with yeast infections have inappropriate medication, but empirical, pre-
emptive use of antifungal therapy is still questionable and not recommended [153].
Adverse eects of anti-fungals may vary from renal failure because of vasoconstriction
(conventional amphotericin B) through visual disturbances, phototoxicity or skin rash
(voriconazole) and hepatotoxicity (posaconazole, voriconazole). Itraconazole and other
azole medications are well tolerated with only rare and mild cases of hepatotoxicity,
but widely used uconazole is prescribed for prophylaxis and treatment for a longer
period, deteriorating its eectiveness. Hypersensitivity developed against an azole com-
pound may trigger adverse reactions against other azoles. Also, administration of
uconazole is not recommended in non-albicans Candida infections. Besides novel
laboratory techniques, multiple risk assessment scores were developed to help in the
decision of whether to introduce anti-fungal therapy, but further validation is needed
before introduction into wide clinical use [11, 155]. The above mentioned data emphasise
the importance of the proper indication of antimicrobial treatment. Considering the
above discussed shortcomings of generally used microbiological identication systems
and risk assessment scores, we think our MP measurement based PAC1+ and CD42a+
PMP measurements can provide valuable additional information on mixed fungal sepsis
Chapter 5. Discussion 52
prone patients following the admission to the intensive care unit. According to our
current knowledge, there is no evidence that fungal infections or antifungal medications
alter platelet or PMP measurement results.
In our second MP study, we aimed to assess MP number and prole changes in severe
sepsis and related organ dysfunction, while also aimed to provide further data regarding
MP amounts in severe sepsis compared to controls. We found increased numbers of
total MPs in severe septic patients compared to controls. Especially, platelet derived MP
numbers were elevated throughout our study period. Our results are in concordance with
Mostefai et al. who also reported increased MP numbers from septic patients compared
to controls [156]. Soriano also found elevated MP numbers in survivor septic patients,
but no dierence in PMP between patients and controls [107]. Joop et al. as formerly
discussed, observed lower MP numbers in septic patients compared to controls [151]. We
and others showed signicantly elevated annexin V+ MPs in sepsis [107, 156]. These
discrepancies may result from dierences in control group selection, sample handling and
patient inclusion time frame. Dierences may also originate from the isolation protocol,
as well as dierent centrifugation protocol or including several washing steps, therefore
losing large portion of MPs during sample processing [157]. Our main goal with strict
control group assessment was to reduce the possible eects of age and underlying patient
history on MP results. We assessed both 7 days and 28 days ICU mortality in our second
MP study. Former ndings of Soriano et al. showed that MPs harbouring activated
endothelial marker (CD62E) was elevated in survivor severe septic patients, as well
as PMPs were not signicantly elevated in survivors. We also did not found signicant
dierence between survivors and non-survivors during our study period [107]. We report
the constant elevation of GPIX (CD42a) positive microparticles, which may contribute to
platelet adhesion to damaged vessel walls and collagen, while activated 2b3 complex
(PAC1 labelled), was decreased during study period. Based on the theory of Lundahl,
some platelets have higher sensitivity toward activation, which may result in the early
activation and consumption [134]. One may speculate that a group of platelets are
activated earlier in sepsis. The consumption of these early-activated platelets may cause
the decrease of PAC1 positivity, but constant CD41 and CD42a presence during our
study. Another explanation for this change is the loss of antibody epitope, resulting
from former brinogen binding by 2b3. In this case, PMPs may form aggregates,
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deteriorating microcirculation. As stated before, a main goal in this study was to
determine MP numbers in the presence of organ dysfunctions. We provide evidence that
the overall number of organ failures have no measurable eect, neither on the total MP
numbers, nor on amounts of various MP subgroups. After the assessment on the eect of
various organ failures on MPs, patients with renal dysfunction on study inclusion showed
overall MP, PMP and myeloid MP increase. The activation of the innate immune system
and inltration of the kidney by monocytes and macrophages contributes to sepsis-
related renal failure [156]. Monocyte-derived microparticles are a main source of blood-
born TF and carry high amounts of phosphatidylserine. Elevation of these microparticles
can cause increased clot formation and obstructions in kidney vessels. CD13 supports
monocyte/endothelial adhesion, therefore increased number of CD13+ particles may aid
the tracking of monocytes, inltration of the kidneys [158] and local TF concentration
increase. Blood ow may deteriorate in inltrated tissue, increasing tissue hypoxia
through local coagulation and cytokine release. Elevated CD42a PMPs are described
in active vasculitis based acute kidney failure [159]. Negative correlation between BUN
and creatinine concentrations and low levels of circulating CD42a PMPs may indicate
attachment of platelets to the damaged renal endothelial surface, promoting vascular
dysfunction resulting elevated BUN and creatinine concentrations. In our study most
pronounced dierences regarding renal dysfunction were observed on inclusion. Patients
admitted to the intensive care unit receive extensive uid therapy and a large variety
of medications, which may explain the loss of the on-admission signicant dierences of
various microparticle groups.
5.1 Limitations of presented studies
Due to the relatively small sample size, clinically our investigations should only be
viewed as a pilot studies. All patients included in the mixed fungal septic group have
suered from C. albicans infection, therefore further (P)MP measurements are needed
to assess our data on Candida strains dierent from albicans and non-Candida fungal
infections to clarify the importance of (P)MPs as an early marker for mixed fungal sepsis.
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5.2 Conclusions
Our hypothesis about the key role of highly inducible platelet aggregation in the devel-
opment of microvascular ow insuciency and patient survival could not be completely
conrmed. Concerning aggregability we found no signicant dierence between sur-
vival and non-survival patients therefore we cannot recommend this test as a mortality
predictor. Our results provided further evidence that platelet aggregation in severe
sepsis can be altered by the actual platelet count. Our main nding in the platelet
aggregation study is spontaneous aggregation in severe septic patients. The development
of spontaneous aggregation may cause local microcirculatory disturbances therefore
further investigations in the eld are required.
Our data revealed that measurement of PAC1 and CD42a positive PMPs can provide
useful and early information in the assessment for mixed C. albicans fungal sepsis, thus
can improve treatment decisions during the care of severe septic patients. We plan
further studies to conrm the clinical usefulness and biological background of similar
PMP alterations in severe septic and multiple organ failure patients.
Although, according to our data MP numbers show no dierence in survivor and non-
survivor patients, our results support the model, that MPs contribute with increased
procoagulant phospholipid surface, TF and monocyte sequestration in patients admitted
to the ICU with severe sepsis and acute sepsis-related renal disorder. These patients
showed negative correlation with serum BUN and creatinine concentrations and CD42a+
platelet-derived microparticles, suggesting the role of these particles in the development
of renal failure. Although we have no rm causality between MP numbers and renal
dysfunction, we would like to emphasise the importance of MPs in the pathomechanism
of sepsis-related renal failure.
Novel ndings
6.1 Novel ndings of the platelet aggregation study
 Inducible platelet aggregation measurements cannot be recommended for severe
sepsis mortality prediction.
 This study was the rst to provide evidence on the presence of increased sponta-
neous platelet aggregation in severe septic patients.
 Our results provided further evidence on the direct proportion of platelet count
and inducible platelet aggregation results.
6.2 Novel ndings of the microparticle studies
 We provided further evidence on increased MP levels in severe sepsis.
 Our clinical study was the rst which showed the MP prole dierence in patients
with severe sepsis complicated with fungal (C. albicans) infection. This nding
could help the development of a future early diagnostic test based on MPs.
 Our novel approach revealed that there is no direct connection between the number
of organ failures and MP numbers.
 Data from our second study support the contribution of MPs in the development
of sepsis-related acute kidney injury.
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